Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629
Discontinued
Reference number: GID-TA10841
The Department of Health has asked NICE to produce guidance on using the above technology in the NHS in England.
The company has informed NICE that it will not provide an evidence submission for this appraisal at this time. Therefore, we are suspending the appraisal while we consider the next steps. NICE will continue to monitor any development and will update interested parties as and when the situation changes.